Ignite Creation Date:
2025-12-24 @ 3:15 PM
Ignite Modification Date:
2025-12-27 @ 12:28 PM
Study NCT ID:
NCT04976192
Status:
COMPLETED
Last Update Posted:
2025-10-07
First Post:
2021-07-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
Sponsor:
Teva Pharmaceuticals USA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-30
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-05
Completion Date Type:
ACTUAL
First Submit Date:
2021-07-14
First Submit QC Date:
None
Study First Post Date:
2021-07-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-27
Results First Submit QC Date:
None
Results First Post Date:
2025-10-07
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-18
Last Update Post Date:
2025-10-07
Last Update Post Date Type:
ESTIMATED